Stopping diabetes in its tracks: Autologous non-myeloablative stem cell transplantation

Georgia Fousteri, Alberto Hayek, Matthias von Herrath

Research output: Contribution to journalArticle

Abstract

A recent report in this year's April issue of Journal of the American Medical Association describes an unprecedented success in delaying insulin dependence in patients with recent-onset Type 1 diabetes after non-myeloablative immune suppression with cyclophosphamide and antithymocyte globulin followed by autologous stem cell transplantation. In this study, 14 out of 15 patients became insulin-independent, which lasted up to 35 months. Concomitantly, C-peptide levels increased substantially compared with preintervention values. Treatment of autoimmune disorders, and in particular Type 1 diabetes, constitutes a complex balancing act between suppressing autoaggressive responses strongly and permanently enough, while circumventing much-feared long-term side effects from chronic immunosuppression. This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes.

Original languageEnglish
Pages (from-to)845-851
Number of pages7
JournalRegenerative Medicine
Volume2
Issue number5
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Stem Cell Transplantation
Medical problems
Stem cells
Type 1 Diabetes Mellitus
Insulin
Phase II Clinical Trials
Clinical Trials, Phase I
Antilymphocyte Serum
C-Peptide
American Medical Association
Cyclophosphamide
Immunosuppression
Peptides
Tuning
Therapeutics

Keywords

  • Anti-CD3
  • Anti-thymocyte globulin
  • Cyclophosphamide
  • Diabetes
  • Human trial
  • Non-myeloablative stem cell transplantation
  • Tregs

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology

Cite this

Stopping diabetes in its tracks : Autologous non-myeloablative stem cell transplantation. / Fousteri, Georgia; Hayek, Alberto; von Herrath, Matthias.

In: Regenerative Medicine, Vol. 2, No. 5, 09.2007, p. 845-851.

Research output: Contribution to journalArticle

Fousteri, Georgia ; Hayek, Alberto ; von Herrath, Matthias. / Stopping diabetes in its tracks : Autologous non-myeloablative stem cell transplantation. In: Regenerative Medicine. 2007 ; Vol. 2, No. 5. pp. 845-851.
@article{a21248deb0bf4b3f83de1d024c25ed4c,
title = "Stopping diabetes in its tracks: Autologous non-myeloablative stem cell transplantation",
abstract = "A recent report in this year's April issue of Journal of the American Medical Association describes an unprecedented success in delaying insulin dependence in patients with recent-onset Type 1 diabetes after non-myeloablative immune suppression with cyclophosphamide and antithymocyte globulin followed by autologous stem cell transplantation. In this study, 14 out of 15 patients became insulin-independent, which lasted up to 35 months. Concomitantly, C-peptide levels increased substantially compared with preintervention values. Treatment of autoimmune disorders, and in particular Type 1 diabetes, constitutes a complex balancing act between suppressing autoaggressive responses strongly and permanently enough, while circumventing much-feared long-term side effects from chronic immunosuppression. This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes.",
keywords = "Anti-CD3, Anti-thymocyte globulin, Cyclophosphamide, Diabetes, Human trial, Non-myeloablative stem cell transplantation, Tregs",
author = "Georgia Fousteri and Alberto Hayek and {von Herrath}, Matthias",
year = "2007",
month = "9",
doi = "10.2217/17460751.2.5.845",
language = "English",
volume = "2",
pages = "845--851",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Stopping diabetes in its tracks

T2 - Autologous non-myeloablative stem cell transplantation

AU - Fousteri, Georgia

AU - Hayek, Alberto

AU - von Herrath, Matthias

PY - 2007/9

Y1 - 2007/9

N2 - A recent report in this year's April issue of Journal of the American Medical Association describes an unprecedented success in delaying insulin dependence in patients with recent-onset Type 1 diabetes after non-myeloablative immune suppression with cyclophosphamide and antithymocyte globulin followed by autologous stem cell transplantation. In this study, 14 out of 15 patients became insulin-independent, which lasted up to 35 months. Concomitantly, C-peptide levels increased substantially compared with preintervention values. Treatment of autoimmune disorders, and in particular Type 1 diabetes, constitutes a complex balancing act between suppressing autoaggressive responses strongly and permanently enough, while circumventing much-feared long-term side effects from chronic immunosuppression. This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes.

AB - A recent report in this year's April issue of Journal of the American Medical Association describes an unprecedented success in delaying insulin dependence in patients with recent-onset Type 1 diabetes after non-myeloablative immune suppression with cyclophosphamide and antithymocyte globulin followed by autologous stem cell transplantation. In this study, 14 out of 15 patients became insulin-independent, which lasted up to 35 months. Concomitantly, C-peptide levels increased substantially compared with preintervention values. Treatment of autoimmune disorders, and in particular Type 1 diabetes, constitutes a complex balancing act between suppressing autoaggressive responses strongly and permanently enough, while circumventing much-feared long-term side effects from chronic immunosuppression. This clinical Phase I/II trial is relevant to fine-tuning interventive protocols and contributing to the further development of suitable combination therapies to prevent and treat Type 1 diabetes.

KW - Anti-CD3

KW - Anti-thymocyte globulin

KW - Cyclophosphamide

KW - Diabetes

KW - Human trial

KW - Non-myeloablative stem cell transplantation

KW - Tregs

UR - http://www.scopus.com/inward/record.url?scp=35048846482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35048846482&partnerID=8YFLogxK

U2 - 10.2217/17460751.2.5.845

DO - 10.2217/17460751.2.5.845

M3 - Article

C2 - 17907936

AN - SCOPUS:35048846482

VL - 2

SP - 845

EP - 851

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 5

ER -